Eli Lilly's Stellar Earnings and Breakthrough Therapy Status: A Game Changer for Investors
Eli Lilly's earnings beat and FDA milestone could redefine its market trajectory.
Arrowhead Pharmaceuticals' Strategic Acquisition: Priority Review Voucher for Plozasiran
Arrowhead's acquisition of a Priority Review Voucher is set to reshape its market strategy and impact its stock.
Eton Pharmaceuticals Expands Portfolio with ASN-001 Acquisition
Eton Pharmaceuticals enhances its pipeline with the acquisition of ASN-001, targeting the infantile hemangioma market.
Johnson & Johnson's Robotic Surgery Breakthrough: A Game Changer for Investors
FDA approval of J&J's OTTAVA system sparks optimism, positioning the company as a strong contender in surgical robotics.
Pfizer's Strategic Shift: Navigating Beyond Covid Revenue
Pfizer's recent Q2 earnings reflect a pivot to non-Covid products as Covid revenue expectations are reduced.
Sunshine Biopharma's New Drug Approval: A Strategic Move into Women's Health
Sunshine Biopharma's approval of a generic drug opens doors to a lucrative women's health market worth $5.2 billion.
Pfizer's Q2 Earnings Beat: A Post-Pandemic Perspective
Pfizer's Q2 earnings exceeded expectations, signaling strong performance from non-COVID products amid adjusted revenue forecasts.
Eli Lilly's FDA Approval: A Catalyst for Market Momentum
Eli Lilly's recent FDA approval sparks momentum in LLY's stock and the broader market, with the Dow rising significantly.
Curium and Lantheus Merger: A Game-Changer for Radiopharmaceuticals
Curium and Lantheus' $8 billion merger could reshape the radiopharmaceutical landscape and offer significant benefits to shareholders.
Integer Holdings to Go Private: Analyzing the KKR Acquisition
Integer Holdings is set to be acquired by KKR for $5.7 billion, raising questions about the future of the medical device sector.
Supernus and Indivior Merger: A New Era for CNS Biopharmaceuticals
Supernus and Indivior's all-stock merger could reshape the CNS biopharmaceutical landscape significantly.
Curium's $8 Billion Acquisition of Lantheus: What it Means for Investors
Curium's $8 billion acquisition of Lantheus could reshape the radiopharmaceutical landscape. Here's what investors need to know.











